Grundläggande statistik
| CIK | 753772 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medizone International, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| October 19, 2020 |
OMB APPROVAL OMB Number: 3235-0167 Expires: May 31, 2021 Estimated average burden hours per response 1. |
|
| May 11, 2018 |
Financial Statements and Exhibits, Other Events, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2018 MEDIZONE INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Number |
|
| May 11, 2018 |
Medizone International Announces Filing of Voluntary Chapter 7 Bankruptcy Proceeding Exhibit 99.1 Medizone International Announces Filing of Voluntary Chapter 7 Bankruptcy Proceeding Kalamazoo, Michigan, May 8, 2018. Medizone International, Inc. (OTCQB:MZEI), or Medizone, manufacturer of the AsepticSure® system, announced that it today has filed a voluntary petition in bankruptcy seeking liquidation of the Company pursuant to Chapter 7 of the United States Bankruptcy Code. The pet |
|
| April 25, 2018 |
MZEI / Medizone International, Inc. RW MEDIZONE INTERNATIONAL, INC. 350 East Michigan Avenue, Suite 500 Kalamazoo, Michigan 49007 April 25, 2018 VIA E-MAIL AND EDGAR SUBMISSION Securities and Exchange Commission Attention: John Reynolds Division of Corporate Finance Mail Stop 3561 100 F Street N.W. Washington, D.C. 20549 Re: Medizone International, Inc. Withdrawal of Registration Statement on Form S-1, File No. 333-224119 Ladies and Ge |
|
| April 24, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2018 MEDIZONE INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Num |
|
| April 24, 2018 |
Exhibit 99.2 Medizone International Announces Commencement of Involuntary Bankruptcy Proceedings Against the Company Kalamazoo, Michigan, April 20, 2018. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® system, today announced that certain creditors of the Company have commenced an involuntary bankruptcy proceeding under Chapter 11 of the United States Bankru |
|
| April 24, 2018 |
UNITED STATES BANKRUPTCY COURT EX-99 2 ex99-1.htm EX-99.1 Exhibit 99.1 B 5 (Official Form 5) (12/07) FORM 5. INVOLUNTARY PETITION UNITED STATES BANKRUPTCY COURT INVOLUNTARY PETITION IN RE (Name of Debtor – If Individual: Last, First, Middle) Medizone International, Inc. ALL OTHER NAMES used by debtor in the last 8 years (Include married, maiden, and trade names.) Last four digits of Social-Security or other Individual's Tax-I.D |
|
| April 17, 2018 |
MZEI / Medizone International, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ☒ Definitive Proxy Sta |
|
| April 13, 2018 |
MZEI / Medizone International, Inc. S-1/A Registration No. 333- 224119 As filed with the Securities and Exchange Commission on April 13 , 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 5122 87-0412648 (State or other jurisdiction of inco |
|
| April 6, 2018 |
MZEI / Medizone International, Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ☐ Definitive Proxy Sta |
|
| April 3, 2018 |
MZEI / Medizone International, Inc. S-1 Registration No. 333- As filed with the Securities and Exchange Commission on April 3, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 5122 87-0412648 (State or other jurisdiction of incorporation) (Primary Standard |
|
| March 27, 2018 |
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Shareholder Update 3-27-2018 Dear fellow shareholders, Previously, I provided you my initial Shareholder Update, addressing our goals, critical achievements under pursuit, and the values to which we’re committed as a Company. With this update, I wish to report on the status and progress related to our goals and critical achievements. While our overriding g |
|
| March 27, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 medizone8k032618.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2018 MEDIZONE INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) |
|
| March 22, 2018 |
MZEI / Medizone International, Inc. RW MEDIZONE INTERNATIONAL, INC. 350 East Michigan Avenue, Suite 500 Kalamazoo, Michigan 49007 March 22, 2018 VIA E-MAIL AND EDGAR SUBMISSION Securities and Exchange Commission Attention: John Reynolds Division of Corporate Finance Mail Stop 3561 100 F Street N.W. Washington, D.C. 20549 Re: Medizone International, Inc. Withdrawal of Registration Statement on Form S-1, File No. 333-222991 Ladies and Ge |
|
| March 20, 2018 |
Exhibit 10.23 FIRST AMENDMENT TO EQUITY PURCHASE AGREEMENT THIS FIRST AMENDMENT TO EQUITY PURCHASE AGREEMENT (the “Amendment”), dated as of March 16, 2018, is made and entered into by and among Medizone International, Inc., a Nevada corporation (the “Company”), L2 Capital, LLC, a Kansas limited liability company (“L2”), and SBI Investments LLC, 2014-1, a statutory series of Delaware limited liabil |
|
| March 20, 2018 |
Exhibit 10.12 CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT THIS CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT (the “Addendum”) is made and entered into as of the 10th day of November, 2017, by and between Medizone International, Inc., a Nevada corporation (the “Company”), and Dr. Michael E. Shannon (“Executive” or “you”). The Company and Executive entered into that certain Emplo |
|
| March 20, 2018 |
Exhibit 21 Subsidiaries of the Registrant Medizone Canada, Inc. Canadian Foundation for Global Health |
|
| March 20, 2018 |
MZEI / Medizone International, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| February 12, 2018 |
S-1 1 medizone-s1020818.htm S-1 Registration No. 333- As filed with the Securities and Exchange Commission on February 12, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 5122 87-0412648 (State or other jurisdiction |
|
| February 12, 2018 |
Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use in this Registration Statement on Form S-1 of our report dated March 22, 2017 with respect to the consolidated balance sheets of Medizone International, Inc. |
|
| February 12, 2018 |
Exhibit 21 Subsidiaries of the Registrant Medizone Canada, Inc. Canadian Foundation for Global Health |
|
| February 12, 2018 |
EX-10.21 2 ex10-21.htm EX-10.21 Exhibit 10.21 AMENDED AND RESTATED TRADING AGREEMENT This Amended and Restated Trading Agreement (this “Agreement”), effective as of the 11th day of February, 2018 (the “Effective Date”), is entered into by and between L2 Capital, LLC (“L2”) and SBI Investments LLC, 2014-1 (“SBI,” and together with L2, the “Parties” and each, a “Party”). WHEREAS, each of the Parties |
|
| February 5, 2018 |
Exhibit 10.8 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of January 31, 2018, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the "Company"), L2 CAPITAL, LLC, a Kansas limited liability company (“L2”), and SBI INVESTMENTS LLC, 2014-1, a statutory series of Delaware limited liability company (“SBI”) (together with their respective perm |
|
| February 5, 2018 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of January 31, 2018, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation, with headquarters located at 350 East Michigan Avenue, Suite 500, Kalamazoo, Michigan 49007 (the ?Company?), and L2 CAPITAL, LLC, a Kansas limited liability company, with its address at 8900 State Line Rd., |
|
| February 5, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2018 MEDIZONE INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File N |
|
| February 5, 2018 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 31, 2018, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation, with headquarters located at 350 East Michigan Avenue, Suite 500, Kalamazoo, Michigan 49007 (the “Company”), and SBI INVESTMENTS LLC, 2014-1, a statutory series of Delaware limited liability company, with i |
|
| February 5, 2018 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| February 5, 2018 |
EX-10.6 7 ex10-6.htm EX-10.6 Exhibit 10.6 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEP |
|
| February 5, 2018 |
Medizone Announces Completion of Financing EX-99.1 11 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone Announces Completion of Financing Kalamazoo, Michigan, January 31, 2018. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® system, today announced that it raised $250,000 of net proceeds from the completion of a financing transaction, which included the issuance of a $285,000 convertible note and the creation |
|
| February 5, 2018 |
Exhibit 10.4 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| February 5, 2018 |
EX-10.7 8 ex10-7.htm EX-10.7 Exhibit 10.7 EQUITY PURCHASE AGREEMENT This EQUITY PURCHASE AGREEMENT is entered into as of January 31, 2018 (this "Agreement"), by and among Medizone International, Inc., a Nevada corporation (the "Company"), L2 Capital, LLC, a Kansas limited liability company (“L2”), and SBI Investments LLC, 2014-1, a statutory series of Delaware limited liability company (“SBI”) (to |
|
| February 5, 2018 |
Exhibit 10.3 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| February 5, 2018 |
EX-10.9 10 ex10-9.htm EX-10.9 Exhibit 10.9 TRADING AGREEMENT This Trading Agreement (this “Agreement”), dated as of the 31st day of January, 2018 (the “Effective Date”), is entered into by and between L2 Capital, LLC (“L2”) and SBI Investments LLC, 2014-1 (“SBI,” and together with L2, the “Parties” and each, a “Party”). WHEREAS, each of the Parties entered into a Securities Purchase Agreement (the |
|
| February 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2018 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File N |
|
| February 1, 2018 |
Exhibit 10.1 AGREEMENT This Agreement (the ? Agreement?) is entered into effective as of January 30, 2018 (the ? Effective Date?), by and between Medizone International, Inc., a Nevada corporation (the ? Company?), and Jude P. Dinges, a resident of the State of Georgia (? Executive?). RECITALS A. The Company desires to employ Executive as its Executive Vice President ? Commercial Operations. Execu |
|
| February 1, 2018 |
EX-10.2 3 ex10-2.htm EX-10.2 Exhibit 10.2 CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT THIS CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT (the “Addendum”) is made and entered into as of the 30th day of January, 2018, by and between Medizone International, Inc., a Nevada corporation (the “Company”), and Jude P. Dinges (“Executive” or “you”). The Company and Executive entered into |
|
| February 1, 2018 |
Medizone International Appoints Jude Dinges to Executive Team Exhibit 99.1 Medizone International Appoints Jude Dinges to Executive Team Kalamazoo, Michigan, January 30, 2018. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure ? system, today announced the appointment of Jude P. Dinges, as its Executive Vice President - Commercial Operations. Before joining Medizone, Mr. Dinges, served as Senior Vice President, Chief Comme |
|
| December 5, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File N |
|
| December 5, 2017 |
Exhibit 99.1 Shareholder Update Dear fellow shareholders, I?ve had the pleasure of serving as CEO of Medizone International, Inc. (?Medizone?) for three months. During this time, many of you have communicated with me, conveying your best wishes for me in this position, as well as expressing various comments related to our business. Thank you for your well wishes and support. Also, your input and c |
|
| November 8, 2017 |
MZEI / Medizone International, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| November 3, 2017 |
Exhibit 10.1 AGREEMENT This Agreement (the “ Agreement”) is entered into effective as of November 1, 2017 (the “ Effective Date”), by and between Medizone International, Inc., a Nevada corporation (the “ Company”), and Philip A. Theodore, a resident of the State of South Carolina (“ Executive”). RECITALS A. The Company desires to employ Executive as its Executive Vice President – Operations and Ad |
|
| November 3, 2017 |
The AsepticSure® Disinfection System Introduced to Nordic Region Exhibit 99.3 PRESS RELEASE The AsepticSure ® Disinfection System Introduced to Nordic Region AsepticSure â, the only disinfection system in the world that routinely achieves a minimum microbial kill of at least a thousand times greater than conventional cleaning methods , will be distributed in the Nordic Region by Aglon a/s Stavanger, Norway and Kalamazoo, Michigan, October 30, 2017. Medizone Int |
|
| November 3, 2017 |
Medizone International Appoints Philip Theodore to Executive Team Exhibit 99.1 Medizone International Appoints Philip Theodore to Executive Team Kalamazoo, Michigan, October 31, 2017. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure ? Disinfection System, today announced the appointment of Philip A. Theodore, as its Executive Vice President ? Operations and Administration, General Counsel and Corporate Secretary. Before join |
|
| November 3, 2017 |
Exhibit 10.2 CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT THIS CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT (the “ Addendum”) is made and entered into as of the 1st day of November, 2017, by and between Medizone International, Inc., a Nevada corporation (the “ Company”), and Philip A. Theodore (“ Executive” or “ you”). The Company and Executive entered into that certain Employm |
|
| November 3, 2017 |
Exhibit 10.3 CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT THIS CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT (the “ Addendum”) is made and entered into as of the 1st day of November, 2017, by and between Medizone International, Inc., a Nevada corporation (the “ Company”), and Stephanie L. Sorensen (“ Executive” or “ you”). The Company and Executive entered into that certain Empl |
|
| November 3, 2017 |
Medizone International concludes exclusive Product Supply and License Agreement with Innovasource Exhibit 99.2 Medizone International concludes exclusive Product Supply and License Agreement with Innovasource Kalamazoo, Michigan, November 1, 2017. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure ® Disinfection System, today announced the conclusion of an exclusive Product Supply and License Agreement (the “Supply Agreement”) with Innovasource, LLC, a leadi |
|
| November 3, 2017 |
MZEI / Medizone International, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File N |
|
| October 16, 2017 |
The AsepticSure® Disinfection System, a revolutionary disinfection technology, Receives CE Mark Exhibit 99.1 The AsepticSure® Disinfection System, a revolutionary disinfection technology, Receives CE Mark Kalamazoo, Michigan, October 16, 2017. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Disinfection System, today announced that it is now allowed to place the “CE” Mark on the AsepticSure® System for distribution in the European Union (EU) and its me |
|
| October 16, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 medizone8k101617.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdi |
|
| September 19, 2017 |
Medizone International announces the appointment of David A. Dodd as new Chief Executive Officer Exhibit 99.1 Contact: John Pentony Medizone International, Inc. Telephone: (415) 331-0202 Email: [email protected] POST Monday September 18, 2017 at 7:00 AM EST Medizone International announces the appointment of David A. Dodd as new Chief Executive Officer Kalamazoo, MI, September 18, 2017 ? Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure?, a revolutionary disinfe |
|
| September 19, 2017 |
EX-10.2 3 ex10-2.htm EX-10.2 Exhibit 10.2 CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT THIS CHANGE OF CONTROL ADDENDUM TO THE EMPLOYMENT AGREEMENT (the “Addendum”) is made and entered into as of the 19th day of September, 2017, by and between Medizone International, Inc., a Nevada corporation (the “Company”), and David A. Dodd (“Executive” or “you”). The Company and Executive entered int |
|
| September 19, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File |
|
| September 19, 2017 |
EX-99.2 5 ex99-2.htm EX-99.2 Exhibit 99.2 AsepticSure® Medizone International, Inc.Investor Update – September 18, 2017 1 September 18, 2017 – 10:00 – 10:30 AM ESTToll free for North America: 1-800-681-1924Toll call outside North America: 1-303-223-4393A recording of the call will be available from 9/18/17-9/25/17:1-800-633-8284 Conference ID: 21859116 Investor Update 9/18/17 Safe Harbor Statement |
|
| September 19, 2017 |
Exhibit 10.1 AGREEMENT This Agreement (the ? Agreement?) is entered into effective as of September 15, 2017 (the ? Effective Date?), by and between Medizone International, Inc., a Nevada corporation (the ? Company?), and David A. Dodd, a resident of the State of South Carolina (? Executive?). RECITALS A. The Company desires to employ Executive as its Chief Executive Officer and to obtain Executive |
|
| August 28, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdiction of incorporation) (Commiss |
|
| August 28, 2017 |
Medizone International Announces Next Steps with FDA on AsepticSure® Exhibit 99.1 Medizone International Announces Next Steps with FDA on AsepticSure ? Medizone International prepares plans to submit a marketing application to FDA for use of AsepticSure as a medical device Kalamazoo, Michigan, Friday, August 25, 2017 ? Medizone International, Inc. (OTCQB: MZEI) announced that it has received a written response from the U.S. Food and Drug Administration (?FDA?) on t |
|
| August 24, 2017 |
Medizone International Announces a Change in the Board of Directors EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International Announces a Change in the Board of Directors Press Release on Wednesday August 23, 2017 8:30 AM EST Dwayne Montgomery to step down from the Board of Directors of Medizone International Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone |
|
| August 24, 2017 |
8-K 1 medizone8k082417.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdic |
|
| August 8, 2017 |
MZEI / Medizone International, Inc. 10-Q (Quarterly Report) 10-Q 1 medizoneintl10q063017.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| June 22, 2017 |
EX-99.4 5 ex99-4.htm EX-99.4 Exhibit 99.4 AsepticSure® Medizone International, Inc.Investor Update – June 21, 2017 1 June 21, 2017 – 4:00 – 5:00 PM ESTToll free for North America: 1-800-681-1924Toll call outside North America: 1-303-223-4393A recording of the call will be available from 6/21/17-6/28/17:1-800-633-8284 Conference ID: 21854308 Investor Update 6/21/17 Safe Harbor Statement This invest |
|
| June 22, 2017 |
Medizone International Registered to Exhibit AsepticSure at the Military Health System’s Vendor Day EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International Registered to Exhibit AsepticSure at the Military Health System’s Vendor Day AsepticSure registration at the Military Health System’s Vendor Day presents opportunity to demonstrate several applications for the Department of Defense KALAMAZOO, Mich., June 20, 2017 /PRNewswire/ - Medizone International, Inc. (OTCQB: MZEI) announces the |
|
| June 22, 2017 |
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 AsepticSure® Receives Full Approval of International Electrical Safety Standards AsepticSure approval of international safety standards clears path for global commercialization KALAMAZOO, Mich., June 21, 2017 /PRNewswire/ - Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone |
|
| June 22, 2017 |
Medizone International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdiction of incorporation) (Commissio |
|
| June 22, 2017 |
Medizone International Announces a Retirement from the Board of Directors Exhibit 99.3 Medizone International Announces a Retirement from the Board of Directors June 21, 2017 – Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) the developer of AsepticSure, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healt |
|
| June 8, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdiction of incorporation) (Commission |
|
| June 8, 2017 |
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International Expands Global Sales Potential by Addressing the Death Care Industry with AsepticSure Post on Thursday June 8, 2017 8:00 AM EST Recent study highlights the potential of AsepticSure to provide superior cleaning to mortuary preparation areas within funeral homes Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) announces the c |
|
| May 31, 2017 |
Exhibit 99.1 Medizone International Expands Commercial Team to Address Growing Global Opportunity in Bioterrorism Countermeasures and Public Health Preparedness Internationally recognized expert Brad Goble to lead Medizone’s efforts to capitalize on government efforts to address bioterrorism countermeasures and public health risks Kalamazoo, Michigan – May 30, 2017 - Medizone International, Inc. ( |
|
| May 31, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 medizone8k053117.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdictio |
|
| May 23, 2017 |
8-K 1 medizone8k052217.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdictio |
|
| May 23, 2017 |
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International Continues Board of Directors Expansion to Support Executing on the Launch of AsepticSure in Key Global Markets New Medizone Board member Steve Meyer will add significant commercial experience to deliver on the company’s growth plans Kalamazoo, Michigan, May 22, 2017 - Medizone International, Inc. (OTCQB: MZEI) announces the appointme |
|
| May 12, 2017 |
Medizone International 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| April 25, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdiction of incorporation) (Commissi |
|
| April 25, 2017 |
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International Announces Sales Agreement with Innovasource LLC KALAMAZOO, MICH. April 24, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens, announced today that the Co |
|
| April 7, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 medizone8k040717.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) |
|
| April 7, 2017 |
Medizone International Announces Next Steps on AsepticSure® Exhibit 99.1 Medizone International Announces Next Steps on AsepticSure ? POSTED ON APRIL 7, 2017 Medizone International prepares plans to submit AsepticSure for FDA approval as a medical device Kalamazoo, Michigan, Friday, April 7, 2017 ? Medizone International, Inc. (OTCQB: MZEI) announced that in a scheduled conference call late Thursday, April 6, 2017, with representatives of the U.S. Food and |
|
| April 6, 2017 |
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International Expands Board of Directors to Support Executing on the Launch of AsepticSure in Key Global Markets New Medizone Board Member, Dwayne Montgomery, will play critical role in the company’s growth plans Medizone International, Inc. (MZEI:OB MZEI:QB) (Kalamazoo, MI) announces the addition of Dwayne Montgomery to the Board of Directors. Me |
|
| April 6, 2017 |
Medizone International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Numb |
|
| March 22, 2017 |
Medizone International 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| March 3, 2017 |
Exhibit 99.1 Conference call script Medizone International, Inc. March 2, 2017 David Esposito, Chairman and Chief Executive Officer, Medizone International, Inc. Thank you (operator) Carlos. Welcome to today’s call. Thank you for joining us today. I am David Esposito and I am joined remotely by Dr Michael Shannon our President & Director of Medical Affairs and John Pentony who leads our Investor R |
|
| March 3, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Numb |
|
| March 1, 2017 |
Medizone International to Host Investor Conference Call Exhibit 99.1 Contact: John Pentony Medizone International, Inc. Telephone: (269) 202-5020 Email: [email protected] Medizone International to Host Investor Conference Call KALAMAZOO, MICH. March 1, 2017 ? Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure?, the only EPA cleared hospital room disinfection technology that combines ozone and hydrogen peroxide to achieve u |
|
| March 1, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Numb |
|
| March 1, 2017 |
Exhibit 99.2 |
|
| February 28, 2017 |
Medizone International announces the appointment of a new Chairman and Interim CEO EXHIBIT 99.1 Contact: John Pentony Medizone International, Inc. Telephone: (415) 331-0202 Email: [email protected] Medizone International announces the appointment of a new Chairman and Interim CEO San Francisco, CA. February 27, 2017 ? Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure?, the only EPA cleared hospital room disinfection technology that combines ozone a |
|
| February 28, 2017 |
EX-10.3 4 ex10-3.htm EX-10.3 EXHIBIT 10.3 SEPARATION AND RELEASE AGREEMENT THIS SEPARATION AND RELEASE AGREEMENT (this “Agreement”) is made and entered into as of the 28th day of February 2017, by and between Jill Marshall (“Executive”), and MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the “Company”). RECITALS Executive’s last day of employment with the Company will be February 28, 2017 (th |
|
| February 28, 2017 |
EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Agreement (the “ Agreement”) is entered into effective as of March 1, 2017 (the “ Effective Date”), by and between Medizone International, Inc., a Nevada corporation (the “ Company”), and David A. Esposito (“ Executive”). RECITALS A. The Company desires to employ Executive as its Chairman and Interim Chief Executive Officer and Executive desires to be employe |
|
| February 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File |
|
| February 28, 2017 |
EXHIBIT 10.2 SEPARATION AND RELEASE AGREEMENT THIS SEPARATION AND RELEASE AGREEMENT (this ? Agreement?) is made and entered into as of the 28 th day of February 2017, by and between Edwin G. Marshall (? Executive?), and MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the ? Company?). RECITALS Executive?s last day of employment with the Company will be February 28, 2017 (the ? Separation Date?) |
|
| February 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File |
|
| February 27, 2017 |
Certificate of Amendment to Articles of Incorporation (4) EX-3.1 2 ex3-1.htm EX-3.1 EXHIBIT 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 76.390) Filed in the office of Barbara K. Cegaske Secretary of State State of Nevada Document Number 20170031024-00 Filing Date and Time 01/04/2017 10:48AM Entity Number C5866-1 |
|
| January 25, 2017 |
Certificate of Amendment to the Articles of Incorporation dated January 24, 2017. EXHIBIT 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www . nv sos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 76.390) Filed in the office of Barbara K. Cegaske Secretary of State State of Nevada Document Number 20170031024-00 Filing Date and Time 01/04/2017 10:48AM Entity Number C5866-1984 USE BLACK INK ONLY |
|
| January 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2017 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File N |
|
| December 19, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2016 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File |
|
| November 10, 2016 |
Medizone International 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| November 4, 2016 |
Medizone International DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ? Definitive Proxy Sta |
|
| October 27, 2016 |
Exhibit 10.2 MEDIZONE INTERNATIONAL, INC. WARRANT ([warrant holder]) THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ? ACT?), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE EXERCISED BY OR ON BEHALF OF ANY US PERSON UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EF |
|
| October 27, 2016 |
Amended and Restated Distribution Agreement dated as of October 21, 2016 (10) Exhibit 10.1 AMENDED AND RESTATED DISTRIBUTION AND LICENSE AGREEMENT by and between MEDIZONE INTERNATIONAL, INC. and GYD S.A. This Amended and Restated Distribution and License Agreement (“ Agreement”), effective as of October 21, 2016, is entered into by Medizone International, Inc., a Nevada corporation, with its principal executive offices at 4000 Bridgeway, Suite 401, Sausalito, California 949 |
|
| October 27, 2016 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2016 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File N |
|
| October 27, 2016 |
Medizone International, Manufacturer of AsepticSure, Closes Additional Investment EX-99.1 4 ex99-1.htm EX-99.1 Exhibit 99.1 Medizone International, Manufacturer of AsepticSure, Closes Additional Investment San Francisco, CA October 27, 2016. Medizone International, Inc. (The Company) (MZEI:QB) manufacturers of the un-paralleled AsepticSure® Hospital Disinfection System, announces its South American distribution partner and investment group GYD S.A. operating in South America un |
|
| October 7, 2016 |
Executive Employment Agreement with Stephanie L. Sorensen dated October 1, 2016 (6) EXHIBIT 10.1 AGREEMENT This Agreement (the ? Agreement?) is entered into effective as of October 1, 2016 (the ? Effective Date?), by and between Medizone International, Inc., a Nevada corporation (the ? Company?), and Stephanie L. Sorensen (? Sorensen?). RECITALS A. The Company desires to employ Sorensen as its Chief Financial Officer and Sorensen desires to be employed by the Company as its Chief |
|
| October 7, 2016 |
Medizone International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2016 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Nu |
|
| September 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2016 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File |
|
| August 25, 2016 |
Medizone International DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ? Definitive Proxy Sta |
|
| August 19, 2016 |
Medizone International DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 19, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2016 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Nu |
|
| August 15, 2016 |
Medizone International 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| August 15, 2016 |
Medizone International 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| August 5, 2016 |
Medizone International DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ? Definitive Proxy Sta |
|
| August 4, 2016 |
2016 Equity Incentive Award Plan (8) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ☒ Definitive Proxy Sta |
|
| July 25, 2016 |
Medizone International PRE 14A DRAFT: 19 July 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 12, 2016 |
Promissory Note for payments of past due compensation to Michael Shannon, dated July 6, 2016 Exhibit 10.5 $111,109.00 July 6, 2016 PROMISSORY NOTE This PROMISSORY NOTE (this ? Note?) is made as of July 6, 2016 between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (? Maker?) and DR. MICHAEL SHANNON (? Holder?). WHEREAS, Holder is currently serving as Director of Medical Affairs and President of Maker; and WHEREAS, Maker owes Holder One Hundred Eleven Thousand One Hundred Nine Dollars |
|
| July 12, 2016 |
Executive Employment Agreement with Edwin G. Marshall, dated effective July 6, 2016 EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of July 6, 2016 (the “Effective Date”), by and between Medizone International, Inc., a Nevada corporation (the “Company”), and Edwin Marshall (“Executive”). RECITALS A. The Executive is currently employed by the Company as its Chief Executive O |
|
| July 12, 2016 |
Promissory Note for payments of past due compensation to Jill Marshall, dated July 6, 2016 Exhibit 10.4 $444,583.00 July 6, 2016 PROMISSORY NOTE This PROMISSORY NOTE (this ? Note?) is made as of July 6, 2016 between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (? Maker?) and DR. JILL MARSHALL (? Holder?). WHEREAS, Holder is currently serving as Director of Operations of Maker and is a party to that certain Executive Employment Agreement, dated July 6, 2016, by and between Maker an |
|
| July 12, 2016 |
Executive Employment Agreement with Jill Marshall, dated effective July 6, 2016 EX-10.2 3 ex10-2.htm EX-10.2 Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of July 6, 2016 (the “Effective Date”), by and between Medizone International, Inc., a Nevada corporation (the “Company”), and Dr. Jill Marshall (“Executive”). RECITALS A. The Executive is currently employed by the Company as its Director of Op |
|
| July 12, 2016 |
Promissory Note for payments of past due compensation to Edwin G. Marshall, dated July 6, 2016 Exhibit 10.3 PROMISSORY NOTE $1,065,189.00 July 6, 2016 This PROMISSORY NOTE (this ? Note?) is made as of July 6, 2016 between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (? Maker?) and EDWIN MARSHALL (? Holder?). WHEREAS, Holder has served as the Chief Executive Officer of Maker since April 1998 and is a party to that certain Executive Employment Agreement, dated July 6, 2016, by and betwe |
|
| July 12, 2016 |
Medizone International 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2016 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Numbe |
|
| May 13, 2016 |
Medizone International 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| May 6, 2016 |
Executive Employment Agreement with Boyd G. Evans, dated effective April 30, 2016 ex10-1.htm Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of April 30, 2016 (the “Effective Date”), by and between Medizone International, Inc., a Nevada corporation (the “Company”), and Boyd Evans (the “Executive”). RECITALS A. The Company desires to employ the Executive as its Chief Financial Officer and the Executiv |
|
| May 6, 2016 |
medizone8k050616.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2016 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D |
|
| March 3, 2016 |
Medizone International 10-K (Annual Report) 10-K 1 medizone10k123115.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 17, 2015 |
ex99-1.htm Exhibit 99.1 The AsepticSure? Hospital Disinfection System Introduced to South America AsepticSure?, the only hospital disinfection system in the world that achieves 100% bactericidal kill, dramatically reducing new rates of hospital acquired infections in the rooms treated, will be distributed in South America by GYD S.A. Santiago, Chile and San Francisco, California, November 17, 2015 |
|
| November 17, 2015 |
Distribution Agreement dated effective November 12, 2015 ex10-1.htm Exhibit 10.1 Execution Version DISTRIBUTION AND LICENSE AGREEMENT by and between MEDIZONE INTERNATIONAL, INC. and GYD S.A. This Distribution and License Agreement (the ?Agreement?), effective as of November 12, 2015 (the ?Effective Date?), is entered into by Medizone International, Inc., a Nevada corporation, with its principal executive offices at 4000 Bridgeway, Suite 401, Sausalito, |
|
| November 17, 2015 |
ex10-2.htm Exhibit 10.2 MEDIZONE INTERNATIONAL, INC. Subscription Agreement () THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF THE SECURITIES DESCRIBED HEREIN. THE PURCHASE OF THE SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD BE CONSIDERED ONLY BY |
|
| November 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2015 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 2-93277-D 87-0412648 (State or other jurisdiction of incorporation) (Commi |
|
| November 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| September 9, 2015 |
AsepticSure Proposed for Saudi Arabia to help eliminate MERS-coronavirus ex99-1.htm Exhibit 99.1 AsepticSure Proposed for Saudi Arabia to help eliminate MERS-coronavirus San Francisco, California, September 8, 2015. Medizone International, Inc. (The Company) (OTCBB: MZEI, OTCQB: MZEI), manufacturers of the AsepticSure® Hospital Disinfection System, are pleased to announce the recent sale and delivery of the initial two AsepticSure systems to Al-Hidaya International Med |
|
| September 9, 2015 |
medizone8k090915.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2015 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-9327 |
|
| July 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| April 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| February 13, 2015 |
Compensation Committee Charter Exhibit 20.2 COMPENSATION COMMITTEE CHARTER of MEDIZONE INTERNATIONAL, INC. Membership The Compensation Committee (the “Committee”) of the board of directors (the “Board”) of Medizone International, Inc., a Nevada corporation (the “Company”), shall consist of two or more directors. Each member of the Committee shall be independent in accordance with the provisions of Rule 10C-1(b)(1) under Securit |
|
| February 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| February 13, 2015 |
Exhibit 20.1 AUDIT COMMITTEE CHARTER of MEDIZONE INTERNATIONAL, INC. Membership The Audit Committee (the ?Committee?) of the board of directors (the ?Board?) of Medizone International, Inc. (the ?Company?) shall consist of three or more directors. Each member of the Committee shall be independent in accordance with the requirements of Rule 10A-3 of the Securities Exchange Act of 1934 and the rules |
|
| December 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2014 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File |
|
| December 17, 2014 |
Exhibit 99.1 Year End Chairman’s Message December 17, 2014 Bloomberg News in a recent article originating out of the UK stated that superbug infections could cost the global economy $100 trillion by 2050. One paragraph of the article quoted a former Goldman Sachs Group economist as saying, “If unchecked, the infections may mean 10 million extra deaths a year, with an impact on global wealth roughl |
|
| October 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 10-Q 1 medizone10q093014.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| October 9, 2014 |
8-K 1 medizone8k100914.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2014 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation |
|
| October 9, 2014 |
AsepticSure Developer Medizone International Welcomes Vincent C. Caponi to the Board of Directors EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 AsepticSure Developer Medizone International Welcomes Vincent C. Caponi to the Board of Directors San Francisco, October 8, 2014 – Medizone International, Inc. (OTCQB: MZEI) (OTCBB: MZEI) is pleased to announce that Mr. Vincent C. Caponi has joined our Board of Directors. Mr. Caponi currently serves as the Executive Chairman of the Board of St. Vincent Hea |
|
| August 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| July 17, 2014 |
Medizone International, Inc. 2014 Equity Incentive Plan EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 MEDIZONE INTERNATIONAL, INC. 2014 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Equity Incentive Plan are to attract and retain the best available personnel for positions of substantial responsibility, to align the interests of Service Providers with those of the Company’s stockholders, and to promote the success of the Company’s business |
|
| July 17, 2014 |
MZEI / Medizone International, Inc. S-8 - - S-8 S-8 1 medizone-s8071614.htm S-8 As filed with the Securities and Exchange Commission on July 17, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIZONE INTERNATIONAL, INC. (Exact name of issuer as specified in its charter) Nevada 87-0412648 (State or other jurisdiction of incorpora |
|
| June 4, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2014 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Numbe |
|
| June 4, 2014 |
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 |
|
| April 29, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| February 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2014 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File |
|
| February 28, 2014 |
Exhibit 99.1 AsepticSure moves closer to US launch as Medizone International’s Board of Directors is expanded to add significant Business Development and Strategy Strength New Medizone Board Member David Esposito - Key Commercial Leader For Phadia Sale to Thermo Fisher Scientific for $3.5 Billion USD Medizone International, Inc. (MZEI:OB MZEI:QB) announces the addition of David Esposito to the Boa |
|
| February 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| October 31, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 10-Q 1 medizone10q093013.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| July 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| May 1, 2013 |
Medizone International, Inc. Chairman’s Shareholder Update May 2013 Exhibit 99.1 Medizone International, Inc. Chairman’s Shareholder Update May 2013 Given the recent upswing in our share price, many of you have might be asking ‘what triggered this high-volume buying activity in MZEI?’ Thus, it seems an appropriate time to share an overview of management’s assessment of where we are and where we are headed. Wood Wyant Agreement On April 11th we announced that Wood |
|
| May 1, 2013 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2013 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File Number |
|
| April 26, 2013 |
10-Q 1 medizone10q033113.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| March 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2012 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| December 6, 2012 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2012 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 2-93277-D (Commission File N |
|
| December 6, 2012 |
Letter from HJ Associates & Consultants, LLP, dated December 5, 2012. Exhibit 16.1 December 5, 2012 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, DC 20549 Ladies and Gentlemen: We have read the statements of Medizone International, Inc. pertaining to our firm included under Item 4.01 of Form 8-K dated December 3, 2012, and agree with such statements as they pertain to our firm. Sincerely, /s/ HJ Associates & Consultants, LLP HJ Associates & C |
|
| November 2, 2012 |
424B3 1 medizone424b3-110112.htm Filed Pursuant to Rule 424(b)(3) and (c) File Number 333-171524 Prospectus Supplement No. 2 to Prospectus dated March 19, 2012 66,666,667 Shares of Common Stock of MEDIZONE INTERNATIONAL, INC. This Prospectus Supplement No. 2 supplements the Prospectus of Medizone International, Inc. (“Medizone” or the “Company”) dated March 19, 2012 (the “Prospectus”), relating to |
|
| October 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| August 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| May 10, 2012 |
424B3 1 medizone424b3-051012.htm Filed Pursuant to Rule 424(b)(3) and (c) File Number 333-171524 Prospectus Supplement No. 1 to Prospectus dated March 19, 2012 66,666,667 Shares of Common Stock of MEDIZONE INTERNATIONAL, INC. This Prospectus Supplement No. 1 supplements the Prospectus of Medizone International, Inc. (“Medizone” or the “Company”) dated March 19, 2012 (the “Prospectus”), relating to |
|
| May 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| March 20, 2012 |
MEDIZONE INTERNATIONAL, INC. 66,666,667 Shares Common Stock MEDIZONE INTERNATIONAL, INC. 66,666,667 Shares Common Stock This prospectus relates to the resale of up to 66,666,667 shares of our Common Stock, $0.001 par value per share (“Common Stock”) by Mammoth Corporation (“Mammoth” or the “Selling Stockholder”), which are shares that we will issue to Mammoth pursuant to an equity financing facility (the “Equity Line”) established pursuant to the terms of |
|
| March 14, 2012 |
As filed with the Securities and Exchange Commission on March 14, 2012 Registration No. |
|
| March 14, 2012 |
Exhibit 4.1 MEDIZONE INTERNATIONAL, INC. 2012 EQUITY INCENTIVE AWARD PLAN TABLE OF CONTENTS Page ARTICLE 1 PURPOSE 1 ARTICLE 2 DEFINITIONS AND CONSTRUCTION 1 ARTICLE 3 SHARES SUBJECT TO THE PLAN 5 3.1. Number of Shares 5 3.2. Stock Distributed 6 3.3. Limitation on Number of Shares Subject to Awards 6 ARTICLE 4 ELIGIBILITY AND PARTICIPATION 6 4.1. Eligibility 6 4.2. Participation 6 4.3. Foreign Par |
|
| March 9, 2012 |
As filed with the Securities and Exchange Commission on March 8, 2012 File No. 333-171524 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO REGISTRATION STATEMENT ON FORM S-1 UNDER THE SECURITIES ACT OF 1933 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 5122 87-0412648 (State or other jurisdiction |
|
| March 9, 2012 |
Consent of HJ Associates & Consultants, LLP Exhibit 23(a) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of Medizone International, Inc. |
|
| February 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year period ended December 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| November 10, 2011 |
424B3 1 medizone424b3110911.htm Filed Pursuant to Rule 424(b)(3) and (c) File Number 333-171524 Prospectus Supplement No. 3 to Prospectus dated March 1, 2011 66,666,667 Shares of Common Stock of MEDIZONE INTERNATIONAL, INC. This Prospectus Supplement No. 3 supplements the Prospectus of Medizone International, Inc. (“Medizone” or the “Company”) dated March 1, 2011, as previously supplemented to dat |
|
| October 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| July 28, 2011 |
424B3 1 medizone424b3072711.htm Filed Pursuant to Rule 424(b)(3) and (c) File Number 333-171524 Prospectus Supplement No. 2 to Prospectus dated March 1, 2011 66,666,667 Shares of Common Stock of MEDIZONE INTERNATIONAL, INC. This Prospectus Supplement No. 2 supplements the Prospectus of Medizone International, Inc. (“Medizone” or the “Company”) dated March 1, 2011, as previously supplemented to dat |
|
| July 26, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| June 9, 2011 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2011 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 002-93277-D 87-0412648 (State or other jurisdiction (Commission (IRS Employer o |
|
| June 9, 2011 |
EXHIBIT 99.1 June 8, 2011 / 03:00PM PDT ? Medizone International, Inc. Conference Call CORPORATE PARTICIPANTS Edwin G. Marshall, Medizone International, Inc. ? Chairman & CEO Tommy Auger ? CFO Jill Marshall ? Operations PRESENTATION Jill - Operations Good afternoon and welcome to the Medizone International, Investor Conference Call. This is Dr. Jill Marshall. I am the Director of Operations at Med |
|
| June 9, 2011 |
Medizone International Announces Teleconference, June 8, 2011 EXHIBIT 99.2 PRESS RELEASE Medizone International Announces Teleconference, June 8, 2011 SAN FRANCISCO, CA-(Marketwire - 06/08/11) - Medizone International, Inc. (OTC.BB:MZEI - News) (OTCQB: MZEI) will hold a teleconference with the CEO this afternoon at 3:00 PM Pacific Daylight Time. To listen in, the following numbers are available: US/Canada Number: (916) 209-4534 Back-Up: (619) 276-6333 EU & U |
|
| May 17, 2011 |
424B3 1 medizoneprospectussupplement.htm MEDIZONE PROSPECTUS SUPP 5-17-11 Filed Pursuant to Rule 424(b)(3) and (c) File Number 333-171524 Prospectus Supplement No. 1 to Prospectus dated March 1, 2011 66,666,667 Shares of Common Stock of MEDIZONE INTERNATIONAL, INC. This Prospectus Supplement No. 1 supplements the Prospectus of Medizone International, Inc. (“Medizone” or the “Company”) dated March |
|
| May 4, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| March 3, 2011 |
EX 99.1 to Medizone Form 8-K filed 3-3-11 EX 99.1 to Medizone Form 8-K filed 3-3-11 Former-Deputy Surgeon General Canada Appointed President of Medizone International SAN FRANCISCO, CA-(Marketwire - 02/28/11) - Medizone International, Inc. (OTC.BB:MZEI - News) (Pinksheets:MZEI - News) is pleased to announce the appointment of eminent Canadian medical research scientist, Michael E. Shannon M.A.,M.Sc.,M.D., as President of the Company. In 2 |
|
| March 3, 2011 |
MEDIZONE INTERNATIONAL, INC. 66,666,667 Shares Common Stock MEDIZONE INTERNATIONAL, INC. 66,666,667 Shares Common Stock This prospectus relates to the resale of up to 66,666,667 shares of our Common Stock, $0.001 par value per share (?Common Stock?) by Mammoth Corporation (?Mammoth? or the ?Selling Stockholder?), which are shares that we will issue to Mammoth pursuant to an equity financing facility (the ?Equity Line?) established pursuant to the terms of |
|
| March 3, 2011 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2011 |
Converted by EDGARwiz As filed with the Securities and Exchange Commission on February 16, 2011 File No. |
|
| February 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 333-171524 MEDIZONE IN |
|
| January 27, 2011 |
MEDIZONE INTERNATIONAL, INC. 66,666,667 Shares Common Stock MEDIZONE INTERNATIONAL, INC. 66,666,667 Shares Common Stock This prospectus relates to the resale of up to 66,666,667 shares of our Common Stock, $0.001 par value per share (?Common Stock?) by Mammoth Corporation (?Mammoth? or the ?Selling Stockholder?), which are shares that we will issue to Mammoth pursuant to an equity financing facility (the ?Equity Line?) established pursuant to the terms of |
|
| January 25, 2011 |
As filed with the Securities and Exchange Commission on January 24, 2011 Registration No. |
|
| January 4, 2011 |
S-1 1 mzeis11230final3a.htm MEDIZONE S-1 REG 1-3-11 As filed with the Securities and Exchange Commission on January 3, 2011 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 5122 87-0412648 (State or |
|
| January 4, 2011 |
Exhibit 21 ? Subsidiaries of Registrant Name Place of Incorporation Medizone International, Inc. Delaware Medizone Canada, Ltd. Province of British Columbia, Canada Canadian Foundation for Global Health Ottawa, Canada |
|
| January 3, 2011 |
Medizone International, Inc. Appoints New Chief Financial Officer Medizone International, Inc. Appoints New Chief Financial Officer SAN FRANCISCO, CALIFORNIA, January 3, 2011 ? Medizone International, Inc. (OTCBB: MZEI.OB) (?Medizone? or the ?Company?), a research and development company engaged in developing its AsepticSure? technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infr |
|
| January 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2010 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 002-93277-D 87-0412648 (State or other jurisdiction (Commission (IRS Emplo |
|
| January 3, 2011 |
Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 3, 2011 |
Medizone International, Inc. Appoints New Chief Financial Officer EX-99 to Medizone Form 8-K/A filed 1-3-11 Medizone International, Inc. Appoints New Chief Financial Officer SAN FRANCISCO, CA-(Marketwire - 01/03/11) - Medizone International, Inc. (OTC.BB:MZEI - News) announced today that its Board of Directors has approved the appointment of Thomas (Tommy) E. Auger as the Company's new Chief Financial Officer, effective December 30, 2010. Mr. Auger is engaged as |
|
| November 23, 2010 |
Medizone International Secures $10,000,000 Funding Commitment Exhibit 99.3 Medizone International Secures $10,000,000 Funding Commitment SAN FRANCISCO, CA-(Marketwire - 11/18/10) - Medizone International, Inc. (OTC.BB:MZEI - News) (Pinksheets:MZEI - News) announced today that it has entered into a common stock purchase agreement establishing a $10,000,000 equity line with Mammoth Corporation of Lake Zurich, IL. The agreement is for a two-year term. Under the |
|
| November 23, 2010 |
EX-99.2 3 mzeiex992rra.htm MAMMOTH REGIS RIGHTS AGR Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT, dated as of November 17, 2010 between Mammoth Corporation (“Purchaser”) and Medizone International, Inc. (the “Company”). WHEREAS, simultaneously with the execution and delivery of this Agreement, the parties shall enter into the Common Stock Purchase Agreement, dated |
|
| November 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2010 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 002-93277-D 87-0412648 (State or other jurisdiction (Commission (IRS Emplo |
|
| November 23, 2010 |
COMMON STOCK PURCHASE AGREEMENT EX-99.1 2 mzeiex991cspa.htm MAMMOTH STOCK PURCHASE AGR Exhibit 99.1 COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of November 17, 2010 by and between Medizone International, Inc. (the “Company”), and Mammoth Corporation (the “Purchaser”). Capitalized terms used in this Agreement and not otherwise defined shall have the meanings ascribed to them |
|
| November 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZON |
|
| August 11, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| May 11, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| March 15, 2010 |
Converted by EDGARwiz Exhibit 10.2 to Medizone 09 December Form 10-K TERMINATION AGREEMENT This Termination Agreement (this “Agreement”) is entered into and made effective as of December 14, 2009 (the “Effective Date”), by and among MEDIZONE INTERNATIONAL, INC., a Nevada corporation (“MZI”), MEDIZONE NEW ZEALAND LIMITED, a New Zealand corporation (“MNZ”), and SOLWIN INVESTMENTS LIMITED, a New Zeal |
|
| March 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE I |
|
| December 1, 2009 |
Exhibit 99 to Medizone Form 8-K 12-1-09 Medizone International takes aim at the Bioterrorism Countermeasures Arena San Francisco, California, December 1, 2009. |
|
| December 1, 2009 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2009 Medizone International, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State of Other Jurisdiction of Incorporation) 002-93277-D 87-0412648 (Commission File Nu |
|
| November 12, 2009 |
Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) EXHIBIT 3.1 TO MEDIZONE 09 SEP 10Q ROSS MILLER Document Number 20090672954-64 Secretary of State Filing Date and Time 9/10/2009 206 North Carson Street Entity Number C5866-1984 Carson City, Nevada 89701-4299 (775) 684 5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuan |
|
| November 12, 2009 |
Articles of Amendment to Articles of Incorporation (3) Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. NONSTATUTORY STOCK OPTION AGREEMENT Exhibit 99.4 EXHIBIT B-2 MEDIZONE INTERNATIONAL, INC. NONSTATUTORY STOCK OPTION AGREEMENT THIS NONSTATUTORY STOCK OPTION AGREEMENT ("Agreement") is made and entered into as of the date set forth below, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the "Company"), and the following Director of the Company ("Optionee"): In consideration of the covenants herein set forth, the par |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. NONSTATUTORY STOCK OPTION AGREEMENT Exhibit 99.3 MEDIZONE INTERNATIONAL, INC. NONSTATUTORY STOCK OPTION AGREEMENT THIS NONSTATUTORY STOCK OPTION AGREEMENT ("Agreement") is made and entered into as of the date set forth below, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the "Company"), and the following Director of the Company ("Optionee"): In consideration of the covenants herein set forth, the parties hereto |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. 2009 INCENTIVE STOCK PLAN Exhibit 99.1 MEDIZONE INTERNATIONAL, INC. 2009 INCENTIVE STOCK PLAN THIS MEDIZONE INTERNATIONAL, INC. 2009 INCENTIVE STOCK PLAN (the "Plan") is designed to retain directors, executives and selected employees and consultants and reward them for making major contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under the Plan thereby prov |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. RESTRICTED STOCK PURCHASE OFFER Exhibit 99.8 EXHIBIT D MEDIZONE INTERNATIONAL, INC. RESTRICTED STOCK PURCHASE OFFER THIS RESTRICTED STOCK PURCHASE OFFER (hereinafter, this "Agreement") is made and entered into as of the date set forth below, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the "Company"), and the employee, director or consultant of the Company named in Section 1(b). ("Grantee"): In consideratio |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. INCENTIVE STOCK OPTION AGREEMENT Exhibit 99.9 EXHIBIT A MEDIZONE INTERNATIONAL, INC. INCENTIVE STOCK OPTION AGREEMENT THIS INCENTIVE STOCK OPTION AGREEMENT ("Agreement") is made and entered into as of the date set forth below, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the "Company"), and the employee of the Company named in Section 1(b) ("Optionee"): In consideration of the covenants herein set forth, the |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. CONSULTANT NONSTATUTORY STOCK OPTION AGREEMENT Exhibit 99.2 MEDIZONE INTERNATIONAL, INC. CONSULTANT NONSTATUTORY STOCK OPTION AGREEMENT THIS CONSULTANT NONSTATUTORY STOCK OPTION AGREEMENT ("AGREEMENT") is made and entered into as of the date set forth below, by and between Medizone International, Inc., a Nevada corporation (the "Company"), and the following consultant to the Company (herein, the "Optionee"): In consideration of the covenants h |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. EMPLOYEE NONSTATUTORY STOCK OPTION AGREEMENT Exhibit 99.6 EXHIBIT B-1 MEDIZONE INTERNATIONAL, INC. EMPLOYEE NONSTATUTORY STOCK OPTION AGREEMENT THIS EMPLOYEE NONSTATUTORY STOCK OPTION AGREEMENT ("Agreement") is made and entered into as of the date set forth below, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the "Company"), and the following employee of the Company ("Optionee"): In consideration of the covenants herein |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. STOCK AWARD AGREEMENT Exhibit 99.7 EXHIBIT C MEDIZONE INTERNATIONAL, INC. STOCK AWARD AGREEMENT THIS STOCK AWARD AGREEMENT ("Agreement") is made and entered into as of the date set forth below, by and between MEDIZONE INTERNATIONAL, INC., a Nevada corporation (the "Company"), and the employee, director or consultant of the Company named in Section 1(b). ("Grantee"): In consideration of the covenants herein set forth, t |
|
| September 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIZONE INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0412648 (State of other jurisdiction of incorporation or organization (I.R.S. Employer Identification No.) 144 Buena Vista, P.O. Box 742, Stinson Beach, California 94970 |
|
| September 14, 2009 |
MEDIZONE INTERNATIONAL, INC. CONSULTANT NONSTATUTORY STOCK OPTION AGREEMENT Exhibit 99.5 EXHIBIT B-3 MEDIZONE INTERNATIONAL, INC. CONSULTANT NONSTATUTORY STOCK OPTION AGREEMENT THIS CONSULTANT NONSTATUTORY STOCK OPTION AGREEMENT ("AGREEMENT") is made and entered into as of the date set forth below, by and between Medizone International, Inc., a Nevada corporation (the "Company"), and the following consultant to the Company (herein, the "Optionee"): In consideration of the |
|
| September 11, 2009 |
Investor Relations 800-953-3350 / web site: www.medizoneint.com E-mail: [email protected] Converted by EDGARwiz Exhibit 99 Medizone International, Inc. Announces OTCBB Listing - San Francisco, California September 8, 2009. Developer of ground-breaking ozone-based hospital sterilization technology - AscepticSure™, Medizone announced today that its common stock has begun trading on the OTC Bulletin Board (MZEI.OB). The company’s common stock was previously quoted on the Pink Sheets. “Whi |
|
| September 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 10, 2009 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 002-93277-D 87-0412648 (State or other jurisdiction (Commission (IRS Empl |
|
| August 31, 2009 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2009 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 002-93277-D 87-0412648 (State or other jurisdiction (Commission (IRS Employe |
|
| August 31, 2009 | ||
| August 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q MEDIZONE INTERNATIONAL INC(Form: 10QSB, Received: 05/13/2002 14:48:07) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| August 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. 1 MEDIZONE INTERNATIONAL INC(Form: 10QSB, Received: 05/13/2002 14:48:07) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A Amendment No. |
|
| August 10, 2009 |
2A314,I+U-O=7)C94UO9&EF:65D*$0Z,C`P.3`X,3`Q-C4R,#4I+U1I=&QE M*$U!24P@4U1/4"`P-3$Q*3X^#65N9&]B:@UX begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C@R(#`@;V)J#3P\+TQI;F5A')E M9@T*,`T*)25%3T8-"B`-"C$P,R`P(&]B:@T\/"],96YG=&@@,3`S+T,@,3`Y M+T9I;'1E-IB8&`08F!@F(,C(!!!@`)&T2#@T*96YD%LW M(#'1=+T5X M=$=3=&%T93P\+T=3,"`Q,#$@,"!2/CX^/B]4>7!E+U!A9V4^/@UE;F1O8FH- M.#4@,"!O8FH-/#PO4W5B='EP92]4<'1OQ7V:HDQQ%][Z^H1\M0.;DO(/2@!2.#P&;N#QBCQ6)&R/C!O^(C"6CNBJ; MD6#D&:D'AIO9E4OD.1$G(CYN;WZV;IIZ^^^>+K+S>[??;9YU]^L=U> |
|
| July 21, 2009 |
CORRESP 1 filename1.htm [MEDIZONE LETTERHEAD] July 21, 2009 Mr. John Reynolds Mr. David Walz Mr. Jay Williamson Mr. Jim Lopez Mail Stop 3561 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Via EDGAR RE: Medizone International, Inc. (SEC File No. 002-93277D) Form 10-K filed March 24, 2009 Dear Sirs: This letter responds to the letter o |
|
| July 17, 2009 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Us |
|
| July 13, 2009 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 13, 2009 Medizone International, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State of Other Jurisdiction of Incorporation) 002-93277-D 87-0412648 (Commission File Numbe |
|
| July 13, 2009 |
Converted by EDGARwiz Exhibit 99 to Form 8-k dated July 13, 2009 MEDIZONE INTERNATIONAL, INC. |
|
| July 10, 2009 |
begin 644 filename1.pdf M)5!$1BTQ+C0-)>+CS],-"C$Y,"`P(&]B:@T\/"],:6YE87)I>F5D(#$O3"`T M.3`W-R]/(#$Y,B]%(#(Y,S(S+TX@,R]4(#0U,C(Y+T@@6R`X.3(@,C4X73X^ M#65N9&]B:@T@("`@("`@("`@("`@("`@#0IX')E9@T*,`T*)25%3T8-"B`@("`@("`@("`@("`-"C(Q."`P(&]B M:@T\/"],96YG=&@@,38T+T,@,38P+T9I;'1EP;@Z09@0B9H`` M`P"6M"+S#0IE;F1S=')E86T-96YD;V)J#3(Q-R`P(&]B:@T\/"],96YG=&@@ M,C@O1FEL=&5R+T9L871E1&5C;V1E+U=;,2`Q(#%=+TEN9&5X6 |
|
| July 7, 2009 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 7, 2009 Medizone International, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State of Other Jurisdiction of Incorporation) 002-93277-D 87-0412648 (Commission File Number |
|
| July 7, 2009 |
EXHIBIT 99 to Form 8-K dated 7-7-09 MEDIZONE INTERNATIONAL, INC. San Francisco, California July 7, 2009, Medizone International, Inc. (MZEI.PK) announces it has established its own BSL2A certified laboratory located in Innovation Park, Queen’s University at Kingston, Ontario, Canada. "This is a fully equipped bio-safety level 2 laboratory dedicated exclusively to Medizone research", stated Dr. Mic |
|
| July 2, 2009 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: þ Preliminary Proxy Statement o Confidential, for Us |
|
| June 15, 2009 |
Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts Converted by EDGARwiz EXHIBIT 99 Medizone Announces That Its AsepticSure(TM) Development Program is Reaching Objectives on Two Fronts SAN FRANCISCO, June 15 /PRNewswire-FirstCall/ - Early results from the second series of trials have demonstrated a 5 log reduction (99. |
|
| June 15, 2009 |
Converted by EDGARwiz SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2009 Medizone International, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State of Other Jurisdiction of Incorporation) 002-93277-D 87-0412648 |
|
| June 3, 2009 |
Converted by EDGARwiz SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2009 Medizone International, Inc. (Exact Name of Registrant as Specified in Its Charter) Nevada (State of Other Jurisdiction of Incorporation) 002-93277-D 87-0412648 ( |
|
| June 3, 2009 |
Medizone International Inc. (MZEI.PK) Medizone announces a second round of trials have begun. Converted by EDGARwiz Medizone International Inc. (MZEI.PK) Medizone announces a second round of trials have begun. San Francisco, California, June 3rd, 2009. Medizone International is pleased to announce the commencement of a second series of laboratory trials of the Company’s AsepticSureÔ hospital sterilization technology, which is intended to build upon the success of its research to date. Dr. |
|
| May 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| March 24, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2009 |
By Action of Unanimous Consent EXHIBIT 14 TO 2008 FORM 10-K By Action of Unanimous Consent The Board of Directors of Medizone International, Inc. |
|
| March 24, 2009 |
LETTER OF UNDERSTANDING EXHIBIT 10.9 TO 2008 FORM 10-K LETTER OF UNDERSTANDING BioZone Corporation, Dr. Guenter B. Moldzio 11026 E. Crestline Circle Englewood, Colorado 80111-3806 and Medizone International, Inc. 144 Buena Vista Stinson Beach, CA 94970 October 23, 2008 BioZone and Medizone hereby agree to the following understanding: 1) BioZone will develop for Medizone International a portable oz |
|
| November 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q MEDIZONE INTERNATIONAL INC(Form: 10QSB, Received: 05/13/2002 14:48:07) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| September 19, 2008 |
As filed with the Securities and Exchange Commission on September 19, 2008 Reg. No. 33 As filed with the Securities and Exchange Commission on September 19, 2008 Reg. No. 33 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medizone International, Inc. (Exact name of registrant as specified in its charter) Nevada 87-0412648 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer identifi |
|
| September 19, 2008 |
EX-10.1 3 exhibit10-1.htm 2008 EQUITY COMPENSATION PLAN Exhibit 10.1 MEDIZONE INTERNATIONAL, INC. 2008 EQUITY COMPENSATION PLAN Medizone International, Inc., a Nevada corporation, (the "Corporation"), hereby adopts this Equity Compensation Plan (the "Plan"), under which Common Stock in Lieu of Cash Compensation Awards (“Awards”) of the Corporation may be granted from time to time to employees, dir |
|
| August 13, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| August 1, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q MEDIZONE INTERNATIONAL INC(Form: 10QSB, Received: 05/13/2002 14:48:07) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| July 23, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) X ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 OR TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, |
|
| July 3, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB MEDIZONE INTERNATIONAL INC(Form: 10QSB, Received: 05/13/2002 14:48:07) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB (Mark One) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| July 1, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB (Mark One) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2007 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| June 27, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB MEDIZONE INTERNATIONAL INC(Form: 10QSB, Received: 05/13/2002 14:48:07) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB (Mark One) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2007 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| June 6, 2008 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 6, 2008 |
MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES U MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES (A Development Stage Company) Consolidated Balance Sheet ASSETS December 31, 2007 CURRENT ASSETS Cash $ - Total Current Assets - PROPERTY AND EQUIPMENT (Net) (Notes 1 and 2) - OTHER ASSETS Receivable from affiliate, net (Note 1) - Total Other Assets - TOTAL ASSETS $ - LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) CURRENT LIABILITIES Accounts payable |
|
| June 3, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB (Mark One) X ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2006 OR TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 2-93277-D MEDIZONE INTERNATIONAL, |
|
| April 5, 2007 |
Commission File Number 002-93277-D U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 002-93277-D (Check One) [X] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q and Form 10-QSB [ ] Form N-SAR For Period Ended: December 31, 2006 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tr |
|
| December 18, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB (Mark One) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2006 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| November 15, 2006 |
Commission File Number 002-93277-D Converted by EDGARwiz U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 002-93277-D (Check One) [ ] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q and Form 10-QSB [ ] Form N-SAR For Period Ended: September 30, 2006 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Rep |
|
| August 17, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB MEDIZONE INTERNATIONAL INC(Form: 10QSB, Received: 05/13/2002 14:48:07) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB (Mark One) X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2006 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 2-93277-D MEDIZONE INTERNATIONAL, INC. |
|
| August 14, 2006 |
Commission File Number 002-93277-D U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 002-93277-D (Check One) [ ] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q and Form 10-QSB [ ] Form N-SAR For Period Ended: June 30, 2006 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transi |
